<DOC>
	<DOCNO>NCT01923298</DOCNO>
	<brief_summary>Estrogen receptor positive breast cancer common type breast cancer anti-estrogen therapy show effective preventing recurrence . Side effect anti-estrogens due estrogen deprivation include hot flash , mood change vaginal dryness/pain . Vaginal symptom include pain , dryness , itching , bleed intercourse frequent urinary tract infection report cause significant morbidity postmenopausal woman higher breast cancer survivor anti-estrogen therapy . Treatment option include vaginal lubricant , Replens etc unfortunately many woman continue persistent symptom . Local estrogen show effective post menopausal woman ( Estring Vagifem ) vaginal symptom . There concern use woman breast cancer give may increase blood estrogen level . Studies do far show show controversial result majority report blood estrogen level change significantly . The major drawback study sample size inadequate accrual . The recent trial report showed significant change blood estrogen level woman breast cancer treat aromatase inhibitor ( anti-estrogen therapy ) vagifem vaginal symptom . The author report result 26 patient report significant change blood estrogen level . We propose study change blood estrogen level postmenopausal woman breast cancer currently aromatase inhibitor treat Estring vaginal symptom .</brief_summary>
	<brief_title>Estradiol Levels Patients Treated With Estring</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Stage IIII estrogen receptor positive breast cancer ( positive estrogen receptor ( ER ) ) positivity define immunohistochemical staining â‰¥ 10 % cell ) adjuvant hormonal therapy aromatase inhibitor ( anastrozole , letrozole exemestane ) Adults 18 year age life expectancy least 3 month Attained menopause defined World Health Organization Criteria ( define permanent cessation menstruation result loss ovarian follicular activity . This recognize occur 12 consecutive month amenorrhea , obvious pathological physiological cause . ) Persistent genitourinary symptom cause discomfort 2 week prior visit physician . Tried least 1 prior pharmacological/ nonpharmacological treatment genitourinary symptom Be inform investigational nature study provide write informed consent accordance institutional federal guideline prior study specific procedure Be willing able comply treatment plan , schedule clinic visit , laboratory test study procedure Patients metastatic breast cancer Have concurrent active nonbreast malignancy except nonmelanoma skin cancer Patients vaginal stenosis Patients unable apply Estring</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>